Background: Thiazolopyrimidines possessed their structural diversity and various
biological activity. Up to date, thiazolopyrimidines derivatives have widespread applications in
pharmaceutical fields. In this article, a series of thiazolopyrimidine derivatives were designed based
on the lead compound structure in our previous studies.
Methods: All the target compounds were synthesized with the coupling reaction, Biginelli reaction
and “one-pot” aldol condensation. Their structures were identified by 1H NMR, 13C NMR spectra
and HRMS. Antitumor activities of the target compounds were evaluated by MTT.
Results: 25 new target compounds were synthesized and they primarily screened through
testing their inhibitory rates against two human tumor cell lines and Compounds 15, 17, 20, 22, 40
exhibited more than 70% inhibitory rate against both MDA-MB-231 and K562. Further assessing
their IC50 against five tumor cell lines, 15 and 22 show advantage over lead compound I in MDAMB-
231, K562 and PC-3.
Conclusion: A series of thiazolopyrimidine derivatives were synthesized and the preliminary
biological evaluation suggest that target compound 22 exhibited better antiproliferative activity
against K562 than gossypol.